Trial
NCT04467281
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
—
Condition
Multiple Myeloma
Intervention
89Zr-DFO-daratumumab
Why stopped
PI left institution and study is being transferred.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-01